Skip to content
  • My Cytovance
  • Careers
Cytovance Biologics
  • CDMO Services
    • Overview
    • Microbial
    • Mammalian
    • Gene Therapy
    • Pre-Commercial
    • Support
  • Your Partner
    • Overview
    • Our Team
    • Facilities
  • Knowledge Library
    • Overview
    • Publications
    • Ingenuity Blog
  • Contact Us
  • My Cytovance
  • Careers
Cytovance Biologics
  • CDMO Services
    • Overview
    • Microbial
    • Mammalian
    • Gene Therapy
    • Pre-Commercial
    • Support
  • Your Partner
    • Overview
    • Our Team
    • Facilities
  • Knowledge Library
    • Overview
    • Publications
    • Ingenuity Blog
  • Contact Us

Ingenuity Blog

Your Molecule Has Met Its Match

Filter by:

Featured

Cytovance and Phenotypeca Collaborate

Cytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial Biomanufacturing

OKLAHOMA CITY, March 11, 2023 — Cytovance Biologics and Phenotypeca Limited (Phenotypeca), a research and development organization with proprietary yeast expression technology that provides key advantages in recombinant protein manufacture, have entered into an agreement to provide optimized...
Read Post

Loading...
Cytovance and Phenotypeca Collaborate

Cytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial Biomanufacturing

OKLAHOMA CITY, March 11, 2023 — Cytovance Biologics and Phenotypeca Limited (Phenotypeca), a research and development organization with proprietary yeast...
Read Post
ping_featured

Cytovance Biologics Announces Ping Zhang as Chief Executive Officer

OKLAHOMA CITY, January 16, 2023 -- Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and...
Read Post
Cytovance-fermenter

Webinar: A Strain Development Strategy To Enhance Screening, Process Development And Scale-Up, Upcoming Webinar Hosted By Xtalks

Any current Good Manufacturing Practice (cGMP) E.coli program must be based on a solid strain development strategy. This thought led...
Read Post
X-talk

Webinar: Downstream Process Development Of A Complicated Fusion Protein, Upcoming Webinar Hosted By Xtalks

The number and variety of protein therapeutics have increased dramatically in recent years. To satisfy therapeutic demand, these molecules must...
Read Post
X-Talk2

Webinar: Process Characterization & Statistical Modeling — Transforming Data Into Knowledge Throughout The Product Lifecycle, Upcoming Webinar Hosted By Xtalks

Process Characterization & Statistical Modeling — Transforming Data into Knowledge Throughout the Product Lifecycle, Upcoming Webinar Hosted by Xtalks. It’s...
Read Post
Avantor-Collaborate

Cytovance Biologics And Avantor Collaborate To Accelerate Plasmid DNA Development For Global Biopharma Market

Cytovance Biologics and Avantor Collaborate to Accelerate Plasmid DNA Development for Global Biopharma Market. Cytovance Biologics and Avantor will accelerate...
Read Post
BIO-2022

Cytovance Biologics To Participate In BIO International Convention 2022

Cytovance Biologics, a global leading contract development and manufacturing provider of microbial, mammalian and plasmid DNA services in clinical and...
Read Post
plasmid-dna-manufacturing

Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing

Cytovance Biologics announces the next webinar of its 2021 series: pDNA Manufacturing: An Optimized Platform Process. The webinar set for...
Read Post
CYT-pDNA

Webinar: Plasmid DNA Manufacturing: An Optimized Platform Process

Cytovance® Biologics announces the next webinar of its 2021 series: pDNA Manufacturing: An Optimized Platform Process. The webinar set for...
Read Post
regulatory-strategies-gene-therapy-product-development

Webinar: Regulatory Strategies for Gene Therapy Product Development

Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial and gene therapy biologics, announces its...
Read Post
nature-technology-hyperGRO

Cytovance Biologics offers Nature Technology Corporation’s proprietary HyperGRO manufacturing platform for plasmid DNA CGMP manufacturing

OKLAHOMA CITY, January 16, 2023 -- Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and...
Read Post
investment-mass-spec-services

Cytovance Biologics Announces an Investment in Mass Spectrometry Services

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the addition of Mass Spectrometry (Mass Spec) to...
Read Post

End of content

No more pages to load

Subscribe to our Newsletter

Vision Statement

We believe in a healthier world where every biologic’s path to commercialization is advanced by a development and manufacturing partner that delivers ingenuity end-to-end.

  • CDMO Services
  • Your Partner
  • Knowledge Library
  • Careers
  • Contact Us
  • My Cytovance

© 2023 Cytovance Biologics